AVNS logo

AVANOS MEDICAL INC

AVNSNYSE
πŸ† #2369 by market capEarnings Nov 3US Equity
$871.17β–Ό $30.84 (βˆ’3.54%)
Simulated price
πŸ””
Track AVNS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.5%
7dβ–² 3386.1%
14dβ–² 3386.1%
30dβ–² 3386.1%
ytdβ–² 7664.4%
1yβ–² 7449.1%
🏦Market Cap
$1.17B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+1.9%
Slowing
πŸ“ŠGross Margin
48.5%
Healthy
πŸ’΅FCF Margin
1.1%
Thin
βš–οΈP/S Ratio
1.6x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$862.10 – $886.62
52-Week Range
$9.30 – $25.49
Volume
$2.63B
Avg Volume
$2.91B
Shares Outstanding
46.8M
Next Earnings
Nov 21, 2026

Fundamentals Snapshot

Annual Revenue
$701M
Last Q Revenue
$182M
P/E Ratio
-16.7
P/S Ratio
1.6x
EPS (TTM)
$-1.50
Dividend Yield
0.00%
Dilution (1yr)
+0.9%

Why Investors Own AVNS

  • βœ“High-growth profile β€” revenue up +53.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 29% gross margin and 15% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AVNS logo

AVANOS MEDICAL INC

AVNS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$701Mβ–² +1.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
49.8%β–Ό βˆ’10.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$62Mβ–Ό βˆ’254.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$43Mβ–Ό βˆ’48.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.4Mβ–² +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$39Mβ–² +$23M YoY
StockOtter Β· stockotter.space

About AVANOS MEDICAL INC

Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Sep 2026

Latest News & Updates